Mitral stenosis resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 85: Line 85:
::❑ R/S ratio in V1 = 1.0 or more
::❑ R/S ratio in V1 = 1.0 or more
::❑ S/R ratio in V6 = 1.0 or more
::❑ S/R ratio in V6 = 1.0 or more
::❑ Late intrinsicoid deflection in V1 (0.035+)
::❑ Incomplete [[RBBB]] pattern
::❑ Incomplete [[RBBB]] pattern
::❑ ST T strain pattern in 2,3,aVF
::❑ ST T strain pattern in leads 2,3,aVF
::❑ [[P pulmonale]] or [[Right atrial enlargement]] or P congenitale
::❑ [[P pulmonale]] or [[right atrial enlargement]] or P congenitale
::❑ S1 S2 S3 pattern in children
::❑ Tall R wave in V1 or qR in V1
::❑ R wave greater than S wave in V1
::❑ R wave progression reversal
::❑ R wave progression reversal
::❑ Inverted [[T wave]] in the anterior precordial leads
::❑ Inverted [[T wave]] in the anterior precordial leads

Revision as of 14:34, 28 March 2014


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Twinkle Singh, M.B.B.S. [2]; Mohamed Moubarak, M.D. [3]

Synonyms and keywords: Mitral valve stenosis; narrowing of mitral valve

Overview

Mitral stenosis refers to abnormal narrowing of mitral orifice, which leads to obstruction of blood flow from left atrium to left ventricle. The most common presentations of mitral stenosis are dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema. Mitral stenosis has a characteristic low-pitched, rumbling diastolic murmur, heard best at the apex during physical examination. The definitive therapy for mitral stenosis include percutaneous balloon valvotomy, surgical mitral valve repair, or mitral valve replacement.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Diagnosis

Shown below is an algorithm summarizing the approach to the initial evluation of mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.[2].
Abbreviations: AF: atrial fibrillation; PMBC: percutaneous mitral ballon commissurotomy; TR: tricuspid regurgitation; S1: First heart sound; P2: Pulmonary component of second heart sound; EKG: Electrocardiogram; TTE: Transthoracic echocardiography; MS: mitral stenosis

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

Pulse

Tachycardia
❑ Reduced pulse pressure
Irregularly irregular (with onset of AF)
❑ Reduced in volume

Head:
❑ Mitral facies

❑ Plethoric cheeks with bluish patches

Neck:
Jugular venous distension

❑ Prominent a wave in right heart failure
❑ Absent a wave in AF
❑ Prominent v wave in TR

Chest:
❑ Left parasternal heave
❑ Loud S1
❑ Loud P2 (indicates pulmonary hypertension)
❑ Opening snap
Murmur

Mid diastolic murmur (low pitched, rumbling)
Holosystolic murmur indicates TR
Graham-Steell murmur indicates pulmonary regurgitation

{{#ev:youtube|HW2pk1icYdM|250}}
Video adapted from Youtube.com

Rales
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order tests:


❑ Perform EKG

Left atrial enlargement
❑ Broad, bifid P wave in lead II (P mitrale)


Picture adapted from en.ecgpedia.org

❑ Biphasic P wave with terminal negative portion

Left atrial enlargement as seen in lead V1
Picture adapted from en.ecgpedia.org

Right ventricular hypertrophy
Right axis deviation of +90 degrees or more
❑ RV1 = 7 mm or more
❑ RV1 + SV5 or SV6 = 10 mm or more
❑ R/S ratio in V1 = 1.0 or more
❑ S/R ratio in V6 = 1.0 or more
❑ Incomplete RBBB pattern
❑ ST T strain pattern in leads 2,3,aVF
P pulmonale or right atrial enlargement or P congenitale
❑ R wave progression reversal
❑ Inverted T wave in the anterior precordial leads
Right axis deviation
QRS complex is positive in leads III and aVF
QRS complex is negative in leads I and aVL



Atrial fibrillation
❑ Absence of P waves
❑ Irregularly irregular heart rate


Picture adapted from Wikidoc.org

❑ Perform chest X-ray

❑ Double right heart border (suggestive of left atrial hypertrophy)
❑ Prominent pulmonary artery
Kerley lines (suggestive of interstitial pulmonary edema)


Picture adapted from Radiopedia.org
❑ Perform transthoracic echocardiography

❑ Assess valve area
❑ Assess disease of other valves
❑ Assess mean pressure gradient
❑ Assess pulmonary artery pressure
❑ Assess suitability of valve morphology for PMBC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:

Myxoma

❑ Obstruct the mitral orifice
❑ Exclude with echocardiography

Atrial fibrillation

❑ Order echocardiography to exclude mitral stenosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Treatment

The filling of the left ventricle depends upon the diastole time which is limited by mitral stenosis. Therefore, slowing the heart rate is crucial in the initial management of mitral stenosis in order to improve the diastole time and consequently improve the filling of the left ventricle.

 
Medical therapy

❑ Consider heart rate control in MS patients with:

❑ Normal sinus rhythm and symptoms present on exercise
AF and fast ventricular response

❑ Consider anticoagulation therapy in MS patients with:

AF
❑ Prior embolic event
Left atrial thrombus
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Shown below is an algorithm summarizing the approach to management of rheumatic mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.[2]
MVA: Mitral valve area; PMBC: Percutaneous mitral ballon commissurotomy; PCWP: Pulmonary capillary wedge pressure; ms: milliseconds; NYHA: New York Heart Association; AF: Atrial fibrillation

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess the presence of symptoms
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptomatic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asymptomatic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess the severity of mitral stenosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess the severity of mitral stenosis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Very severe
❑ MVA ≤ 1 cm2
❑ Pressure half time ≥ 220 ms
Stage D
 
Severe
❑ MVA ≤ 1.5 cm2
❑ Pressure half time ≥ 150 ms
Stage D
 
Progressive
❑ MVA > 1.5 cm2
Pressure half time < 150 ms
 
 
 
Very severe
❑ MVA ≤ 1 cm2
❑ Pressure half time ≥ 220 ms
Stage C
 
 
 
 
 
Severe
❑ MVA ≤ 1.5 cm2
❑ Pressure half time ≥ 150 ms
Stage C
 
 
 
Progressive
❑ MVA > 1.5 cm2
Pressure half time < 150 ms
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess if valve morphology is favorable for PMBC
 
 
 
❑ Perform exercise testing
 
 
 
❑ Assess if valve morphology is favorable for PMBC
 
 
 
 
 
❑ Assess if the new onset AF is present
 
 
 
❑ Monitor patient periodically
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
❑ Assess PCWP on exercise
 
 
 
Yes
 
No
 
No
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Proceed with PMBC
 
If patient is severely symptomatic (NYHA III/IV):
❑ Assess the surgical risk of patient
 
 
If PCWP > 25 mm Hg:
❑ Proceed with PMBC
If PCWP< 25 mm Hg :
❑ Monitor patient periodically
 
 
 
❑ Proceed with PMBC
 
 
 
❑ Monitor patient periodically
 
 
 
❑ Assess if the valve morphology is favorable for PMBC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Proceed with PMBC
 
❑ Proceed with mitral valve surgery
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Proceed with PMBC
 
❑ Monitor patient periodically
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Rheumatic Fever Prophylaxis

Shown below is the table depicting the secondary prophylaxis of rheumatic fever according to the 2014 AHA/ACC guideline for the management of valvular heart disease:[3]

Secondary prevention of rheumatic fever
Penicillin G benzathine 1.2 million units IM every day for 4 weeks
Penicillin V potassium 200 mg orally twice a day
Sulfadiazine 1 g orally once a day
Macrolide antibiotics (in patients allergic to penicillin) Varies


Indications Duration of prophylaxis
Rheumatic fever with carditis and persistent valvular heart disease 10 years or until the patient is 40 years (whichever is longer)
Rheumatic fever with carditis but no valvular heart disease 10 years or until the patient is 21 years (whichever is longer)
Rheumatic fever without carditis 5 years or until the patient is 21 years (whichever is longer)

Do's

References

  1. Tadele, H.; Mekonnen, W.; Tefera, E. (2013). "Rheumatic mitral stenosis in Children: more accelerated course in sub-Saharan Patients". BMC Cardiovasc Disord. 13 (1): 95. doi:10.1186/1471-2261-13-95. PMID 24180350. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.
  3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000031. PMID 24589853.


Template:WikiDoc Sources